Sign up

India Insurance Stocks 2026: LIC, SBI Life, HDFC Life & GIC Re Ranked

By DocStoX Research · Updated 1 July 2026 · 15 min read

India's insurance sector is one of the most structurally underpenetrated in the world — with life insurance penetration at roughly 3% of GDP and general insurance below 1% — yet the 8 companies listed on the NSE together represent over ₹11 lakh crore in combined market capitalisation. The sector split is stark: LIC alone accounts for ₹5.55 lakh crore of that, dwarfing every private insurer combined.

We pulled live data for all 8 listed Indian insurance stocks from the DocStoX dataset (sourced from NSE/BSE audited annual filings) as of July 9, 2026, and ranked them on ROCE, ROE, PAT margin, and valuation multiples. The findings are full of contrasts: the highest ROE in the group (37.8%) belongs to the cheapest stock by P/E (9.65x). The highest PAT margin (18.24%) belongs to a general reinsurer trading below book value. And India's most-owned life insurer by AUM generates less PAT in absolute terms than a reinsurer a quarter its size.

India Insurance Stocks 2026: The Full Data Table

All figures sourced from DocStoX data (NSE/BSE audited annual filings), prices as of July 9, 2026. Market cap in ₹ crore.

  • LIC (LICI): Price ₹438.45 | Mkt Cap ₹5,54,698 Cr | P/E 9.65x | P/B 3.09x | ROE 37.8% | ROCE 35% | PAT ₹57,453 Cr | PAT Margin 5.88% | Revenue ₹9,77,772 Cr | EPS ₹45.42 | Div Yield 2.3% | D/E 0.0
  • SBI Life (SBILIFE): Price ₹1,821.7 | Mkt Cap ₹1,82,688 Cr | P/E 75.65x | P/B 9.63x | ROE 12.7% | ROCE 17% | PAT ₹2,413 Cr | PAT Margin 2.06% | Revenue ₹1,16,888 Cr | EPS ₹24.08 | Div Yield 0.15% | D/E 0.0
  • HDFC Life (HDFCLIFE): Price ₹551.85 | Mkt Cap ₹1,19,100 Cr | P/E 62.29x | P/B 6.94x | ROE 11.3% | ROCE 10% | PAT ₹1,912 Cr | PAT Margin 1.92% | Revenue ₹99,432 Cr | EPS ₹8.86 | Div Yield 0.37% | D/E 0.17
  • ICICI Pru Life (ICICIPRULI): Price ₹490.7 | Mkt Cap ₹71,116 Cr | P/E 44.25x | P/B 5.28x | ROE 12.6% | ROCE 10% | PAT ₹1,608 Cr | PAT Margin 2.54% | Revenue ₹63,357 Cr | EPS ₹11.09 | Div Yield 0.34% | D/E 0.19
  • GIC Re (GICRE): Price ₹362.7 | Mkt Cap ₹63,624 Cr | P/E 6.58x | P/B 0.89x | ROE 14.6% | ROCE 17% | PAT ₹9,662 Cr | PAT Margin 18.24% | Revenue ₹52,986 Cr | EPS ₹55.08 | Div Yield 2.76% | D/E 0.0
  • Max Financial (MFSL): Price ₹1,576.8 | Mkt Cap ₹54,724 Cr | P/E 648.89x | P/B 10.58x | ROE 1.57% | ROCE 3% | PAT ₹106 Cr | PAT Margin 0.22% | Revenue ₹47,674 Cr | EPS ₹2.43 | Div Yield 0% | D/E 0.35
  • Star Health (STARHEALTH): Price ₹603.25 | Mkt Cap ₹35,482 Cr | P/E 54.89x | P/B 3.62x | ROE 9.15% | ROCE 12% | PAT ₹646 Cr | PAT Margin 4.01% | Revenue ₹16,101 Cr | EPS ₹10.99 | Div Yield 0% | D/E 0.05
  • New India Assurance (NIACL): Price ₹183.62 | Mkt Cap ₹30,254 Cr | P/E 21.43x | P/B 0.89x | ROE 4.44% | ROCE 4% | PAT ₹1,417 Cr | PAT Margin 2.85% | Revenue ₹49,782 Cr | EPS ₹8.57 | Div Yield 0.81% | D/E 0.0

LIC: The Outlier — 37.8% ROE at 9.65x Earnings

Life Insurance Corporation of India is the most unusual stock on this list. With revenue of ₹9,77,772 crore and PAT of ₹57,453 crore, LIC is not just the largest insurance company in India — it is one of the largest profit-generating companies on the NSE by absolute PAT, trailing only Reliance Industries and a handful of PSU banks. Yet it trades at 9.65x earnings and a P/B of 3.09x, valuation multiples more typical of a slow-growth PSU than a business posting 37.8% ROE and 35% ROCE.

The discount is structural: LIC's policyholder-first mandate, government ownership (86.1% stake), and a decades-old business model built on an agency force of over 13 lakh agents rather than digital channels have led the market to assign a conglomerate/PSU discount. The EPS of ₹45.42 and a 2.3% dividend yield (the highest in the life insurance segment) are real, but concerns about embedded-value disclosure, the shift of younger policyholders toward private insurers, and the government's divestment timeline have kept institutional interest limited.

LIC's current price of ₹438.45 is down 53.5% from its 52-week high of ₹941.95 — the largest drawdown in the insurance group. Its 52-week low of ₹360.75 is just 18% below the current price. The stock has been in a prolonged re-rating decline from its IPO price of ₹949 (May 2022), and at these levels the question is entirely about whether the embedded-value discount and ROE quality eventually get re-priced, or whether structural concerns continue to weigh.

SBI Life: The Most Profitable Private Life Insurer — at the Steepest Valuation

SBI Life Insurance is the largest private life insurer by PAT in this dataset, with ₹2,413 crore in annual profit at a PAT margin of 2.06% on revenue of ₹1,16,888 crore. Its ROCE of 17% is the highest of the three Nifty 50 private life insurers (HDFCLIFE 10%, ICICIPRULI 10%), and its ROE of 12.7% is the strongest among private life players in the group.

The cost is a P/E of 75.65x and a P/B of 9.63x — the most expensive life insurer by earnings multiple in the group. At a current price of ₹1,821.7, SBI Life has pulled back 14.6% from its 52-week high of ₹2,132 but remains close to its 52-week low band (₹1,700.4). The debt-free balance sheet (D/E 0.0) and the distribution leverage of the SBI banking network — 22,000+ branches cross-selling policies — are the core investment thesis. EPS of ₹24.08 and a modest dividend yield of 0.15%.

HDFC Life: Premium Brand, Below-Average Returns in the Peer Group

HDFC Life Insurance is the second-largest private life insurer by market cap (₹1,19,100 crore) and arguably the most recognisable brand in India's private life insurance market. But its fundamental metrics are the weakest among the three leading private life insurers: ROE of 11.3%, ROCE of 10%, and PAT margin of 1.92% — all below SBI Life and ICICI Pru Life.

At a P/E of 62.29x and P/B of 6.94x, HDFC Life trades at a premium multiple for below-peer returns. Revenue of ₹99,432 crore and PAT of ₹1,912 crore (EPS ₹8.86) are the numbers the market is currently paying 62x for. The stock has been particularly hard hit: the current price of ₹551.85 is down 32.3% from its 52-week high of ₹815 — suggesting the market is already applying a correction to the premium it once paid. Dividend yield is 0.37%.

ICICI Prudential Life: Best PAT Margin Among Private Life Insurers

ICICI Prudential Life Insurance offers the best PAT margin among private life insurers in this dataset at 2.54%, on revenue of ₹63,357 crore and PAT of ₹1,608 crore. ROCE of 10% and ROE of 12.6% are in line with peers. At a P/E of 44.25x — the cheapest of the three leading private life insurers — ICICIPRULI also offers the most moderate valuation in that peer group.

The current price of ₹490.7 is down 30.6% from its 52-week high of ₹706.8 but up 6.8% from its 52-week low of ₹459.5. EPS of ₹11.09 and a dividend yield of 0.34%. D/E of 0.19 — the only private life insurer here with any meaningful leverage. ICICI Pru Life's unit-linked product mix and bancassurance distribution (ICICI Bank network) are the structural levers; it was one of the early ULIP-heavy players and has diversified into protection and annuities over the past four years.

GIC Re: The Hidden Value Play — 18% PAT Margin, P/B Below 1

General Insurance Corporation of India (GIC Re) is the most striking value case in this entire dataset. At a P/E of 6.58x and a P/B of 0.89x — below book value — GIC Re offers the cheapest valuation in the group while running the highest PAT margin at 18.24%. PAT of ₹9,662 crore on revenue of ₹52,986 crore makes GIC Re India's most profitable general insurer by PAT margin, ahead of even the large life insurers on this metric.

ROCE of 17% and ROE of 14.6% are respectable. The balance sheet is debt-free (D/E 0.0). EPS of ₹55.08 and a dividend yield of 2.76% — the highest in the entire group. Book value per share of ₹402 vs a market price of ₹362.7 means investors buying today pay below the stated net asset value for a business generating 14.6% returns on that equity.

The PSU discount is the explanation — GIC Re is 85.78% government-owned, with limited float, minimal analyst coverage relative to its profit scale, and a reinsurance business model that is difficult to underwrite intuitively for retail investors. The current price of ₹362.7 is 13.2% below its 52-week high of ₹417.95 and 4.6% above its 52-week low of ₹346.7. If LIC represents the large-PSU-insurer discount, GIC Re is an even more extreme version of the same phenomenon at a fraction of the market cap.

Star Health: India's Largest Listed Health Insurer — Early-Stage Profitability

Star Health and Allied Insurance is the only standalone health insurer in this list, and it represents a fundamentally different business model from life insurers and reinsurers. Revenue of ₹16,101 crore (the smallest in the group) and PAT of ₹646 crore at a PAT margin of 4.01% — a significant improvement for a health insurer that was loss-making until recently. ROCE of 12% and ROE of 9.15% are below the leading life insurers but show a business that has found operating leverage as the claims ratio has stabilised post-COVID normalisation.

At a P/E of 54.89x and P/B of 3.62x, Star Health is priced for growth — specifically the long-term runway in individual health insurance as India's urban-working-class builds family floater coverage. The current price of ₹603.25 is essentially at its 52-week high of ₹606.0 — only 0.5% off peak. The stock has recovered 44.8% from its 52-week low of ₹416.55. Zero debt (D/E 0.05), no dividend, and a market cap of ₹35,482 crore.

Max Financial: ₹648x P/E — What Is the Market Pricing In?

Max Financial Services is a holding company structure (it holds ~87% of Max Life Insurance, a 50:50 JV co-owned with Axis Bank). The P/E of 648.89x reflects a transitory bottom in reported PAT: ₹106 crore on ₹47,674 crore of revenue (PAT margin 0.22%) and ROE of just 1.57%. These numbers are at the holding-company consolidation level and include amortisation and inter-company adjustments that compress the stated profit far below the economic earnings of the underlying Max Life business.

Investors in MFSL are effectively buying a call option on Max Life's embedded value and its Axis Bank bancassurance partnership — not on the 648x stated P/E. At ₹1,576.8 with a market cap of ₹54,724 crore, the stock is down 16.7% from its 52-week high of ₹1,892.5. Zero dividend. The D/E of 0.35 is the highest in the group. MFSL is the most complex instrument in this set: an investor needs to work at the Max Life level (embedded value, VNB margins) rather than the MFSL consolidated P/E to assess it rationally.

New India Assurance: Cheap General Insurer, Thin Returns

New India Assurance is the second PSU general insurer in the group. Revenue of ₹49,782 crore and PAT of ₹1,417 crore at a PAT margin of 2.85% — far below GIC Re's 18.24% — reflect a direct general insurance business (motor, fire, marine, health) with a higher loss ratio than the reinsurer. ROCE of just 4% and ROE of 4.44% are the weakest pure-insurance returns in the group (excluding MFSL's structural holding-company distortion).

At 21.43x P/E and P/B of 0.89x (also below book value), NIACL is cheaper than all private life insurers but offers structurally thinner returns. EPS of ₹8.57 and dividend yield of 0.81%. The current price of ₹183.62 is 15.8% below its 52-week high of ₹218 and up 57% from its 52-week low of ₹116.97. The turnaround from that 52-week low suggests some improvement in the operating environment, but the return-on-equity at 4.44% does not yet justify a structurally higher valuation.

ROCE Rankings: Where Returns on Capital Are Actually Being Generated

Ranking India's 8 listed insurance stocks by ROCE (DocStoX data, NSE/BSE audited annual filings):

  1. LIC (LICI): 35% ROCE — highest in the group, paradoxically also the cheapest by P/E (9.65x)
  2. SBI Life (SBILIFE): 17% ROCE — best return-on-capital among private life insurers
  3. GIC Re (GICRE): 17% ROCE — tied second, cheapest by P/E (6.58x) after LIC
  4. Star Health (STARHEALTH): 12% ROCE — improving trajectory as health insurer scales
  5. HDFC Life (HDFCLIFE): 10% ROCE — weakest returns among the three leading private life players
  6. ICICI Pru Life (ICICIPRULI): 10% ROCE — in line with HDFC Life, cheaper on P/E
  7. New India Assurance (NIACL): 4% ROCE — thin returns, below-book P/B
  8. Max Financial (MFSL): 3% ROCE — holding-company structure distorts; assess at Max Life level

The ROCE rankings expose the core tension in India's insurance sector: the two stocks with the highest ROCE in the group (LIC at 35%, GIC Re at 17%) are also the two cheapest on P/E (9.65x and 6.58x respectively). Both are PSU-owned. Both trade at or below book value. The three leading private life insurers — SBI Life, HDFC Life, ICICI Pru Life — generate ROCE of 10–17% but command P/E multiples of 44x to 76x.

The valuation premium for private insurers over PSU insurers is not irrational in isolation — private insurers have shown superior new business premium (NBP) growth, better agency and bancassurance productivity, and stronger Value of New Business (VNB) margin disclosures. But the magnitude of the gap (9.65x vs 75.65x for comparable or lower ROCE) encodes a very optimistic growth assumption for the private players and a deeply pessimistic one for PSU names — and history suggests these gaps tend to narrow in either direction over 3–5 year cycles.

Key Themes for Insurance Stocks in H2 FY27

  1. IRDAI product regulation and surrender-value norms: The regulator's revised surrender-value guidelines (effective October 2024) have changed the economics of traditional par and non-par savings products. Insurers with higher protection and pure-term policy mix (SBI Life, ICICI Pru Life) are better insulated; traditional-heavy players face pressure on VNB margins. Product mix reports in Q2 FY27 results will be the primary fundamental signal.
  2. Health insurance loss ratios post-normalisation: Star Health's improvement from loss-making to ₹646 crore PAT has been driven by claims normalisation post-COVID. The next test is whether the health loss ratio holds as medical inflation (hospitalisation costs) rises and the average insured age of the book increases. Any adverse claims data in the monsoon quarter (Q2) is the primary risk to Star Health's P/E multiple.
  3. LIC embedded value and share buyback potential: LIC's embedded value (EV) disclosure has been a persistent source of friction with institutional investors — the EV methodology uses older actuarial assumptions than private peers. Any move toward IFRS 17-aligned or private-sector-comparable EV disclosure would be a significant catalyst for re-rating. Similarly, any announcement of a share buyback by the government (as partial divestment tool) could compress the PSU discount.
  4. GIC Re crop insurance cycle: GIC Re's PAT margin of 18.24% is partly driven by India's Pradhan Mantri Fasal Bima Yojana (PMFBY) crop insurance programme — GIC Re is the mandatory reinsurer. Monsoon quality (June–September 2026) will directly affect crop claims and therefore GIC Re's Q2 profitability. A below-normal monsoon = adverse crop claims = PAT headwind.
  5. Axis Bank JV stake impact on MFSL: Any change in the Axis Bank stake in Max Life — or any announcement regarding the JV structure — would directly affect MFSL's market cap, as the holding-company value is almost entirely derived from its Max Life stake.

The DocStoX Take

India's listed insurance space in 2026 divides into three clearly different investment propositions:

PSU value (LIC, GIC Re): The highest ROCE in the sector (35% and 17% respectively), both trading below or near book value, at single-digit to low-double-digit P/E. GIC Re with its 18.24% PAT margin trading at 6.58x earnings and below book value is the most extreme case of the PSU discount in financial services. LIC's ₹57,453 crore in annual PAT at 9.65x earnings is arguably the most dramatic quality-valuation mismatch on the NSE. These are not growth stocks — they are deep-value situations whose re-rating depends on structural catalysts (disclosure reform, divestment, capital allocation signals) rather than earnings acceleration.

Private life insurers at a growth premium (SBI Life, HDFC Life, ICICI Pru Life): P/E multiples of 44x to 76x for ROCE of 10–17%. The premium encodes expectations of sustained VNB margin expansion, bancassurance-led distribution dominance, and a structural penetration increase in life insurance as India's working-age middle class grows. For the premium to be sustained, these companies need to demonstrate consistent double-digit VNB growth and protection-product mix improvement in FY27 results.

Emerging plays (Star Health, New India Assurance): Star Health's 54x P/E for 12% ROCE reflects a growth-and-scale story that is still being proven in health insurance. New India Assurance's 4% ROCE at 21x P/E is the least compelling risk-reward in the group for a pure-capital-efficiency lens.

For a full ROCE ranking, live price data, DocStoX AI verdicts, and fair-value estimates for all 8 listed Indian insurance stocks, visit docstox.com.

By the DocStoX Desk — This is for informational purposes only and not investment advice. Please consult a SEBI-registered advisor before investing.

Apply this on DocStoX

Screen 6,000+ NSE & BSE stocks on these exact metrics, or ask DoXy, our AI analyst. Open the screener · More guides

Informational and educational purposes only, not investment advice. DocStoX is not a SEBI-registered advisor. Consult a SEBI-registered advisor before investing.